- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ever Supreme Bio Technology Co Ltd (6712)
The Ever Suppeme share price today is 150.50, view TWO 6712 stock exchange data. Track the latest Ever Suppeme share price with real-time updates on 6712 stock performance including market cap, day range, 52-week range and dividend yield. Access 6712 charts, earnings dates and analyst estimates to support your investment decisions.
TPEX
Currency in TWD
150.50
-2.00(-1.31%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
149.50
151.50
52 wk Range
149.50
152.50
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
149.50151.50
52 wk Range
149.50152.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
6712 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Currently not supported.
Analysts Sentiment
Strong Buy
Price Target
225.00
Upside
+49.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Biotechnology industry
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 225.00
(+49.50% Upside)
Earnings
Latest Release
10-08-2026
EPS / Forecast
0.90 / --
Revenue / Forecast
272M / --
Compare 6712 to Peers and Sector
Metrics to compare | 6712 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6712PeersSector | |
|---|---|---|---|---|
P/E Ratio | 32.0x | 30.9x | −0.3x | |
PEG Ratio | 2.78 | 0.00 | 0.00 | |
Price/Book | 5.4x | 3.2x | 2.6x | |
Price / LTM Sales | 14.0x | 6.6x | 2.8x | |
Upside (Analyst Target) | 49.5% | 35.9% | 66.6% | |
Fair Value Upside | Unlock | −5.6% | 9.1% | Unlock |
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products and related businesses; and cell preparations and investment activities in biotechnology and medical industry businesses. Ever Supreme Bio Technology Co., Ltd was incorporated in 2016 and is based in Taichung, Taiwan.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Ever Suppeme (6712) Share Price Today?
The Ever Suppeme share price today is 150.50.
What is the current Ever Suppeme (6712) share price and day range?
As of 31-10-2026, the Ever Suppeme share price is 150.50, with a previous close of 0.00. The share price has ranged from 149.50 to 151.50 today, while the 52-week range spans from 149.50 to 152.50.
What Is the Ever Suppeme Market Cap?
As of today, Ever Suppeme market cap is 15.16B.
Does Ever Suppeme Pay Dividends? What's The Current Dividend Yield?
The Ever Suppeme dividend yield is 2.2%%.
What Is the Ever Suppeme (6712) Share Price Target?
The average 12-month share price target for Ever Suppeme is 225.00, with a high estimate of 225 and a low estimate of 225. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +49.50% Upside potential.
What Is Ever Suppeme's Earnings Per Share (TTM)?
The Ever Suppeme EPS (TTM) is 4.91.
When Is the Next Ever Suppeme Earnings Date?
Ever Suppeme will release its next earnings report on 17-11-2026.
What Stock Exchange Does Ever Suppeme Trade On?
Ever Suppeme is listed and trades on the Taipei Exchange.
What Is the Stock Symbol for Ever Suppeme?
The stock symbol for Ever Suppeme is "6712."
How Many Times Has Ever Suppeme Stock Split?
Ever Suppeme has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.